Enhanced Solid Tumor NGS Panel Broadens Genetic-Variants Detection: Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S.

Answers from the Lab

Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S., explain how Mayo Clinic Laboratories' augmented MayoComplete Solid Tumor Panel better profiles tumor genetics. Defining tumor pathogenesis can guide targeted cancer therapy.

(00:31)
Can you tell us a little about yourself and your background — Beth?

(01:24)
Stephanie, what about you?

(01:42)
Dr. Jenkins, a little bit about yourself and your background, please?

(02:25)
Could you provide a brief overview of the new MayoComplete Solid Tumor assay and the enhancements we've provided?

(04:02)
What changes did you incorporate into the test?

(04:57)
Why are copy number variants and loss of heterozygosity important, and how are they used in patient care?

(07:12)
Does including these genes guide patient care in a more valuable way?

(07:51)
What alternative test options are available and how do they compare to the MayoComplete Solid Tumor Panel?

(10:27)
Is having many options available in a one-stop shop important to help guide patient management?

(11:57)
Do you have anything else you'd like to add about the MCSTP enhancements and what the new test assay will deliver in terms of clinical utility or patient care?